The News
Rakovina Therapeutics has received a 30-day extension from the TSXV for its non-brokered private placement financing, initially announced in January and February 2026.
Why It Matters
This extension allows Rakovina to potentially secure additional funding, which is crucial for advancing its AI-powered cancer therapies. Successful financing could enhance the company's capacity for innovation in drug discovery, impacting the biopharmaceutical landscape.
Key Evidence
The information is sourced from a press release by Rakovina Therapeutics, reported by GLOBE NEWSWIRE, indicating reliability.
Original Article
aktiencheck
DE source 路 Published 3d ago
https://www.aktiencheck.de/news/Artikel-Rakovina_Therapeutics_Announces_Extension_of_Non_Brokered_Private_Placement-19556605